Tivicay (dolutegravir) / ViiV Healthcare - LARVOL DELTA

Successful use of isavuconazole as secondary prophylaxis of cryptococcal meningitis in a person living with HIV and AIDS: a case report. (PubMed, Ther Adv Infect Dis) - "Induction therapy with liposomal amphotericin B (4 mg/kg/day) plus fluconazole (800 mg/day) was prolonged to 10 weeks because flucytosine was initially unavailable; intravenous flucytosine (25 mg/kg q6h) was introduced when accessible. Maintenance fluconazole (800 mg/day) was continued, and antiretroviral therapy (ART) with dolutegravir plus emtricitabine/tenofovir disoproxil was initiated after 8 weeks...Isavuconazole's pharmacokinetic profile, oral availability, and limited antiretroviral drug-drug interactions supported its use as extended secondary prophylaxis in this setting, although limited access in low- and middle-income countries remains a concern. This case highlights isavuconazole as a potential alternative prophylactic strategy when fluconazole is ineffective or not tolerated."

Journal • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • CD4

Safety and efficacy of albuvirtide and dolutegravir for HIV postexposure prophylaxis in men who have sex with men: a prospective non-randomized cohort study. (PubMed, BMC Infect Dis) - No abstract available

Journal • Human Immunodeficiency Virus • Infectious Disease

DORDOL: Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Chelsea and Westminster NHS Foundation Trust | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8 • NEFL

ATYPICAL IGA NEPHROPATHY UNMASKED BY IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A HIV PATIENT (ISN-WCN 2026) - "However, IRIS leading to the unmasking of glomerular diseases is rarely reported.Methods A 42-year-old woman diagnosed with HIV presented with nausea and vomiting for 2 weeks, two months after starting highly active antiretroviral therapy (HAART) containing tenofovir disoproxil fumarate (TDF) 300 mg, lamivudine 300mg, and dolutegravir 50 mg...DIF studies showed mesangial IgA (3+), C3 (1+), and kappa (3+) staining and lambda (1+).Download: Download high-res image (868KB)Download: Download full-size imageResults She was treated with IV methylprednisolone 500 mg for 3 doses, followed by oral prednisolone at 0.5 mg/kg body weight. HAART was modified to an abacavir-based regimen...To conclude, this case emphasizes the need for clinicians to be aware of the diverse renal manifestations of IRIS in the setting of HIV. It also underscores the need for vigilance after initiating HAART."

Clinical • Glomerulonephritis • Human Immunodeficiency Virus • IgA Nephropathy • Immunology • Infectious Disease • Inflammatory Arthritis • Monoclonal Gammopathy • Renal Disease • CD4

Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy. (PubMed, HIV Med) - "In this cross-sectional assessment, no evidence of HBV reactivation was detected in people living with HIV with isolated anti-HBc receiving TFV-sparing dual ART, including regimens without direct anti-HBV activity."

Journal • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study. (PubMed, J Antimicrob Chemother) - "We identified several amino acid substitutions outside the established DRMs that are strongly associated with predicted dolutegravir resistance. Dolutegravir resistance evolution is complex and likely involves mutations not currently classified as DRMs."

Journal • Human Immunodeficiency Virus • Infectious Disease

Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study. (PubMed, J Antimicrob Chemother) - "Our findings indicate that pre-existing IN and RT DRM, including low-abundance and secondary/polymorphic variants, did not compromise the virological efficacy of dolutegravir-based triple therapy in ART-naïve individuals, supporting the high resistance barrier of dolutegravir and the lack of need for baseline resistance testing."

Journal • Next-generation sequencing • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Overcoming barriers, driving progress: Clinical science at IAS 2025. (PubMed, J Int AIDS Soc) - "In the face of growing economic pressures, innovation in HIV treatment and prevention remains essential. The conference emphasized the importance of sustainable public health strategies and individualized care approaches to ensure continued progress in the global HIV response."

Journal • Genetic Disorders • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Obesity • Pediatrics • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Efficient synthesis of 4-pyridone-3-carboxylic acids via the reaction of enaminated diketonates with primary amines. (PubMed, Org Biomol Chem) - "The pyridonation approach can also be implemented under mechanoactivation conditions, which significantly accelerate the reaction. This strategy was applied for the construction of polycyclic 4-pyridone-3-carboxylic acids and a dolutegravir derivative."

Journal

HIV viral non-suppression and drug resistance among persons who inject drugs on dolutegravir antiretroviral therapy in Kenya. (PubMed, medRxiv) - "We enrolled Kenyan PWID who had transitioned from an efavirenz ( EFV ) based regimen to tenofovir+lamivudine+DTG ( TLD ) ≥6 months prior, and measured plasma HIV RNA viral load ( VL ) every 6 months for 2 years...Among 250 participants, 125 were receiving methadone, 199 (79.6) reported heroin use, 70% were male, and median age was 39 years...While NNRTI resistance was common, DTG resistance mutations were rare. Improving viral suppression among PWID living with HIV will reduce transmission risks and improve clinical outcomes."

Journal • Human Immunodeficiency Virus • Infectious Disease

Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co-Infection Using a Rifampicin or Rifabutin-Based Regimen: A Retrospective Observational Case Series. (PubMed, Immun Inflamm Dis) - "This case series preliminarily validated the efficacy of DTG + 3TC when combined with rifabutin-based anti-TB regimens in patients with TB and HIV."

Journal • Observational data • Retrospective data • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4 • CD8

Limited emergence of dolutegravir-associated resistance mutations in HIV-1 across Africa (ESCMID Global 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Effect of 1HP on dolutegravir concentrations (ESCMID Global 2026) - No abstract available

Gene Therapies • Human Immunodeficiency Virus • Infectious Disease

Effect of weight reduction intervention vs standard of care among people living with HIV experiencing significant weight gain from dolutegravir-based regimens: a randomised controlled trial (WISH-DTG trial) (ESCMID Global 2026) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Pharmacokinetics of Dolutegravir in Children with HIV with and without Tuberculosis Coinfection Treated According to World Health Organization Dosing Guidelines. (PubMed, J Acquir Immune Defic Syndr) - "Twice-daily dolutegravir with rifampin was associated with higher trough concentrations in children with HIV/TB than in controls. Standard dose of dolutegravir with rifampin needs to be investigated."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Deciphering the groove-binding mode of dolutegravir with salmon sperm DNA through spectroscopic and molecular modelling approaches. (PubMed, Sci Rep) - "Thermodynamic measurements taken at various temperatures indicate that the interaction is spontaneous (∆G° = -15.0 to -25.4 kJ mol- 1) and primarily driven by hydrogen bonds and van der Waals forces (∆H° = -198.51 kJ mol- 1 and ∆S° = -573.33 J mol- 1 K- 1). Overall, this work provides a foundational framework and a pioneering step for future clinical and pharmacological research, as well as genome integrity assessments, with the ultimate goal of developing DNA-targeted drugs with higher selectivity and effectiveness."

Journal • Human Immunodeficiency Virus • Infectious Disease • Oncology

A 48-week, Randomized Controlled Trial of Doravirine for Individuals with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). (PubMed, Clin Infect Dis) - P4 | "In people with HIV and obesity, switching from an INSTI+TAF/FTC regimen to DOR/FTC with either TAF or TDF did not produce clinically meaningful differences in weight change or metabolic health after 48 weeks."

Journal • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity

Optimizing Salvage ART: Real-World Outcomes of Doravirine Plus DTG or BIC in Heavily Treatment-Experienced Persons Living with HIV. (PubMed, Microorganisms) - "We conducted an observational, real-world-data study on HTE-PWH in active care at the "Victor Babeș" Hospital, Bucharest, receiving doravirine (DOR)-based salvage regimens combined with dolutegravir (DTG) or bictegravir (BIC)...Salvage regimens included BIC/FTC/TAF + DOR (50.0%), 3TC/TDF/DOR + DTG (35.2%), and 3TC/DTG + DOR (14.7%)...Individuals with PM infection were younger and had longer ART exposure than those with heterosexual acquisition. DOR-based salvage regimens combined with DTG or BIC were effective in adherent HTE-PWH, particularly those with extensive ART histories."

Journal • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease • CD4

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025. (PubMed, Euro Surveill) - "The cases are not phylogenetically linked, representing two independent introductions of integrase inhibitor resistant HIV into the Dutch population. These observations highlight the need for strengthened surveillance and prevention efforts in Europe and globally."

Journal • Human Immunodeficiency Virus • Infectious Disease

Real-world use of second-generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS-CO3-AquiVIH-NA cohort. (PubMed, HIV Med) - "In this real-world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle-aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population."

Journal • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Diabetes • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications. (PubMed, Clin Infect Dis) - "Emergent resistance in VF cases often resulted in cross-resistance to other nonnucleoside reverse transcriptase inhibitors and integrase strand transfer inhibitors. Although most cases did not meet the high-risk profile as defined by registration trials, subtype A lineages were overrepresented. Low drug levels were not elevated versus treatment successes. These data suggest that subtype-specific factors beyond A6 may influence VF risk and merit further study."

Journal

Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database. (PubMed, J Antimicrob Chemother) - "This study provides a systematic framework for evaluating post-marketing AEs of INSTIs and NNRTIs using a semi-quantitative scoring system. Our findings identified five high-priority AEs that require clinical validation and further investigation."

Adverse events • Journal • Eosinophilia • Hematological Disorders • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Liver Failure

Decade-long antiretroviral therapy in Uganda: Population-health outcomes from a national HIV treatment cohort, 2014-2024. (PubMed, PLOS Glob Public Health) - "At ART initiation, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens dominated (>90% through 2017), by 2024, > 99% of ART initiations were dolutegravir (DTG)- based, aligning with national policy...Findings show progress alongside persistent gaps and structural barriers. They mandate earlier diagnosis, integrated tuberculosis and non-communicable disease management, strengthened socioeconomic support, and risk-stratified care using predictive modeling to reduce virological failure and drive Uganda toward 95-95-95 targets in resource-constrained settings."

HEOR • Journal • Cardiovascular • Diabetes • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4

Dolutegravir Reduces HTLV-1 Proviral Load and Improves Neurological Outcomes in a Phase II Controlled Trial. (PubMed, Clin Infect Dis) - "In this pilot randomized trial, DTG use was associated with significantly reduced HPVL and improvement in neurofunctional and immunological characteristics of participants in exploratory analyses. These findings provide evidence supporting the use of integrase inhibitors for HTLV-1 infection."

Journal • P2 data • Immune Modulation • Immunology • Infectious Disease • Movement Disorders

Dolutegravir Appears to Lower HTLV-1 Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1 Associated Myelopathy. (PubMed, Clin Infect Dis) - No abstract available

Journal